Showing 4621-4630 of 7598 results for "".
- Valeant Enters Fulfillment Agreements With Walgreenshttps://practicaldermatology.com/news/valeant-enters-fulfillment-agreements-with-walgreens/2458783/Valeant Pharmaceuticals International, Inc. entered into new fulfillment agreements with Walgreens and indicated that it intends to extend this distribution model to additional participating independent retail pharmacies. In conjunction with the fulfillment agreement, Valeant says it will reduce
- FDA Grants ReCell Expedited Access Pathway Designation to Treat Burnshttps://practicaldermatology.com/news/fda-grants-recell-expedited-access-pathway-designation-to-treat-burns/2458782/The FDA has ruled that the ReCell® Autologous Cell Harvesting Device from Avita Medical Ltd. is eligible for earlier regulatory approval for burns treatment. The ruling came under new FDA guidelines called the Expedited Access Pathway (EAP), which are aimed at helping patients get mor
- Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of Commercial Operationshttps://practicaldermatology.com/news/aclaris-therapeutics-inc-appoints-brett-fair-as-senior-vice-president-of-commercial-operations/2458784/Aclaris Therapeutics, Inc. has appointed Brett Fair as Senior Vice President of Commercial Operations. Mr. Fair brings more than 18 years of pharmaceutical commercialization and business
- Valeant Offers Comment on Fake Twitter Accounthttps://practicaldermatology.com/news/valeant-offers-comment-on-fake-twitter-account/2458786/Valeant issued the following statement about a fake Twitter account created to impersonate Mike Pearson: We are aware that someone impersonating Mike Pearson has created an account on Twitter, and we have contacted Twitter to report the unauthorized use. Mike Pearson does not
- Safe, Inexpensive Chemical Found to Reverse Symptoms of Progeria in Human Cellshttps://practicaldermatology.com/news/safe-inexpensive-chemical-found-to-reverse-symptoms-of-progeria-in-human-cells/2458787/New work from the University of Maryland suggests that a common, inexpensive and safe chemical called methylene blue could be used to treat progeria—and possibly the symptoms of normal aging as well. A new study shows for the first time that small doses of methylene blue can almost complete
- ASDS Awards Inagural Research Grant Recipient of Fredric S. Brandt, MD, Innovations in Aesthetics Fellowshiphttps://practicaldermatology.com/news/asds-awards-inagural-research-grant-recipient-of-fredric-s-brandt-md-innovations-in-aesthetics-fellowship/2458790/Abigail Waldman, MD, of Chicago, has been chosen as the inaugural research grant recipient of the Fredric S. Brandt, MD, Innovations in Aesthetics Fellowship Fund. Dr. Waldman was awarded $41,500 for her research project entitled “Patient Motivations and Preferences Regarding the De
- Cosmetic Surgery Forum Wraps Seventh Successful Yearhttps://practicaldermatology.com/news/cosmetic-surgery-forum-wraps-seventh-successful-year/2458791/Covering topics from the appropriate use of permanent fillers to the role of spirituality in practice, the seventh annual Cosmetic Surgery Forum (CSF) brought together experts from multiple specialties at the Aria in Las Vegas this month. The three-day program included guidance on practice manage
- Asian Acne Board and Galderma Join Forces to Improve Understanding and Management of Acnehttps://practicaldermatology.com/news/asian-acne-board-and-galderma-join-forces-to-improve-understanding-and-management-of-acne/2458799/The Asian Acne Board (AAB) and Galderma are inviting candidates to apply for a research grant of $10,000 to contribute to the improvement of best practices in the management of acne. The AAB research grant with the unrestricted support of Galderma is focused on advancing the understa
- Study Finds Increasing Prices for Prescription Dermatology Drugs Since 2009https://practicaldermatology.com/news/study-finds-increasing-prices-for-prescription-dermatology-drugs-since-2009/2458800/A recent study published in JAMA Dermatology found that the price of prescription dermatologic drugs rose considerably from 2009 to 2015, with the vast majority of price increases occurring after 2011. In an effo
- Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Companyhttps://practicaldermatology.com/news/almirall-acquires-veltin-and-altabax-from-stiefel-a-gsk-company/2458802/Almirall has acquired the rights to Veltin® and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino® and an undisclosed cash payment.